Summary:
- This article discusses a scientific study conducted by Neurocrine Biosciences, a pharmaceutical company, on the long-term effectiveness and safety of their drug Ingrezza (valbenazine) in treating tardive dyskinesia in older adults.
- Tardive dyskinesia is a neurological disorder that causes uncontrollable movements, often as a side effect of long-term use of certain medications. The study found that Ingrezza was effective in reducing these movements and had a consistent safety profile over an extended period of time.
- The findings suggest that Ingrezza can be a viable long-term treatment option for older adults suffering from tardive dyskinesia, a condition that can significantly impact their quality of life.